Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft

Journal of Controlled Release

Volumn 146, Issue 1, 2010, Pages 23-30

  Owen, Shawn C ^a   Li, Huan ^b   Sanders, William G ^a   Cheung, Alfred K ^b,c   Terry, Christi M ^b  

^a Florida Center for Advanced Aero Propulsion   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Animal model; Arteriovenous graft; Drug delivery; Hemodialysis; Sirolimus; Vascular access

Indexed keywords

ANIMAL MODEL; ANTI-PROLIFERATIVE; ARTERIOVENOUS GRAFT; DRUG CONCENTRATION; DRUG DISSOLUTION; DRUG RELEASE; HEMODIALYSIS GRAFT; HPLC-MS/MS; IN-VITRO; IN-VIVO; INHIBITORY CONCENTRATION; LADEN POLYMERS; MAGNETIC RESONANCE IMAGES; OPTIMAL DETECTION; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMER DRUGS; POLYMER GELS; PORCINE MODELS; PULSE SEQUENCE; SIROLIMUS; SOLID LOADING; VASCULAR ACCESS; VASCULAR SMOOTH MUSCLE CELLS; VASCULAR TISSUE;

ACIDS; ANIMALS; CELL PROLIFERATION; CONCENTRATION (PROCESS); DIALYSIS; DISEASE CONTROL; DISSOLUTION; DRUG DELIVERY; DRUG PRODUCTS; GELS; HEMODIALYZERS; HISTOLOGY; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MUSCLE; OPTIMIZATION; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; ULTRASONIC APPLICATIONS;

POLYMERS;

MACROGOL; POLITEF; POLYGLACTIN; POLYMER; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY GRAFT; ARTICLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG RELEASE; DRUG SOLUBILITY; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERIZATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SWINE; TISSUE GRAFT; ULTRASOUND; VASCULAR ACCESS; VASCULAR SMOOTH MUSCLE; VEIN ANASTOMOSIS; VEIN GRAFT;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; CAROTID ARTERY, COMMON; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; GELS; GRAFT OCCLUSION, VASCULAR; JUGULAR VEINS; LINEAR MODELS; MAGNETIC RESONANCE ANGIOGRAPHY; MUSCLE, SMOOTH, VASCULAR; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; SIROLIMUS; SOLUBILITY; SUS SCROFA; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 77955304096     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.05.005     Document Type: Article

References (48)

1. Hoffman A.S. Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. 2002, 54(1):3-12.
2. Jeong B., Kim S.W., Bae Y.H. Thermosensitive sol-gel reversible hydrogels. Adv. Drug Deliv. Rev. 2002, 54(1):37-51.
3. He C., Kim S.W., Lee D.S. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J. Control. Release 2008, 127(3):189-207.
4. Zentner G.M., Rathi R., Shih C., McRea J.C., Seo M.H., Oh H., Rhee B.G., Mestecky J., Moldoveanu Z., Morgan M., Weitman S. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 2001, 72(1-3):203-215.
5. Uchegbu I.F., Schätzlein A.G. Polymers in Drug Delivery 2006, CRC/Taylor & Francis, Boca Raton, FL, p. 259.
6. Bergman K., Engstrand T., Hilborn J., Ossipov D., Piskounova S., Bowden T. Injectable cell-free template for bone-tissue formation. J. Biomed. Mater. Res. A 2008.
7. Park J.S., Woo D.G., Yang H.N., Na K., Park K.H. Transforming growth factor beta-3 bound with sulfate polysaccharide in synthetic extracellular matrix enhanced the biological activities for neocartilage formation in vivo. J. Biomed. Mater. Res. A 2008.
8. Yang K.C., Wu C.C., Cheng Y.H., Kuo T.F., Lin F.H. Chitosan/gelatin hydrogel prolonged the function of insulinoma/agarose microspheres in vivo during xenogenic transplantation. Transplant. Proc. 2008, 40(10):3623-3626.
9. Yang K.C., Wu C.C., Lin F.H., Qi Z., Kuo T.F., Cheng Y.H., Chen M.P., Sumi S. Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. Xenotransplantation 2008, 15(6):407-416.
10. Huynh D.P., Im G.J., Chae S.Y., Lee K.C., Lee D.S. Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogel. J. Control. Release 2009.
11. Kim H.K., Shim W.S., Kim S.E., Lee K.H., Kang E., Kim J.H., Kim K., Kwon I.C., Lee D.S. Injectable in situ-forming pH/thermo-sensitive hydrogel for bone tissue engineering. Tissue Eng. A 2009, 15(4):923-933.
12. Lee J., Lee K.Y. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm. Res. 2009, 26(7):1739-1744.
13. Saito M., Takahashi K.A., Arai Y., Inoue A., Sakao K., Tonomura H., Honjo K., Nakagawa S., Inoue H., Tabata Y., Kubo T. Intraarticular administration of platelet-rich plasma with biodegradable gelatin hydrogel microspheres prevents osteoarthritis progression in the rabbit knee. Clin. Exp. Rheumatol. 2009, 27(2):201-207.
14. Swindle K.E., Shah M., Hamilton P.D., Eskin T.A., Kaushal S., Ravi N. Rabbit study of an in situ forming hydrogel vitreous substitute. Invest. Ophthalmol. Vis. Sci. 2009.
15. Vukelja S.J., Anthony S.P., Arseneau J.C., Berman B.S., Cunningham C.C., Nemunaitis J.J., Samlowski W.E., Fowers K.D. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007, 18(3):283-289.
16. DuVall G.A., Tarabar D., Seidel R.H., Elstad N.L., Fowers K.D. Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anticancer Drugs 2009, 20(2):89-95.
17. Elstad N.L., Fowers K.D. OncoGel (ReGel/paclitaxel) - clinical applications for a novel paclitaxel delivery system. Adv. Drug Deliv. Rev. 2009.
18. Schillinger M., Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc. Health Risk. Manag. 2005, 1(1):73-78.
19. Kalan J.M., Roberts W.C. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am. Heart J. 1990, 119(5):1164-1184.
20. Li L., Terry C.M., Shiu Y.T., Cheung A.K. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int. 2008, 74(10):1247-1261.
21. Wang Y., Krishnamoorthy M., Banerjee R., Zhang J., Rudich S., Holland C., Arend L., Roy-Chaudhury P. Venous stenosis in a pig arteriovenous fistula model-anatomy, mechanisms and cellular phenotypes. Nephrol. Dial. Transplant. 2008, 23(2):525-533.
22. Yevzlin A.S. Hemodialysis catheter-associated central venous stenosis. Semin. Dial. 2008, 21(6):522-527.
23. Shi Y., O'Brien J.E., Fard A., Mannion J.D., Wang D., Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996, 94(7):1655-1664.
24. Scott N.A., Cipolla G.D., Ross C.E., Dunn B., Martin F.H., Simonet L., Wilcox J.N. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996, 93(12):2178-2187.
25. De Leon H., Ollerenshaw J.D., Griendling K.K., Wilcox J.N. Adventitial cells do not contribute to neointimal mass after balloon angioplasty of the rat common carotid artery. Circulation 2001, 104(14):1591-1593.
26. Masaki T., Rathi R., Zentner G., Leypoldt J.K., Mohammad S.F., Burns G.L., Li L., Zhuplatov S., Chirananthavat T., Kim S.J., Kern S., Holman J., Kim S.W., Cheung A.K. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. 2004, 66(5):2061-2069.
27. Lipke E.A., West J.L. Localized delivery of nitric oxide from hydrogels inhibits neointima formation in a rat carotid balloon injury model. Acta Biomater. 2005, 1(6):597-606.
28. Pires N.M., Schepers A., van der Hoeven B.L., de Vries M.R., Boesten L.S., Jukema J.W., Quax P.H. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovasc. Res. 2005, 68(3):415-424.
29. Pires N.M., van der Hoeven B.L., de Vries M.R., Havekes L.M., van Vlijmen B.J., Hennink W.E., Quax P.H., Jukema J.W. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials 2005, 26(26):5386-5394.
30. Banno H., Takei Y., Muramatsu T., Komori K., Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J. Vasc. Surg. 2006, 44(3):633-641.
31. Goteti K., Masaki T., Kuji T., Leypoldt J.K., Cheung A.K., Kern S.E. Perivascular tissue pharmacokinetics of dipyridamole. Pharm. Res. 2006, 23(4):718-728.
32. Kuji T., Masaki T., Goteti K., Li L., Zhuplatov S., Terry C.M., Zhu W., Leypoldt J.K., Rathi R., Blumenthal D.K., Kern S.E., Cheung A.K. Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int. 2006, 69(12):2179-2185.
33. Melhem M., Kelly B., Zhang J., Kasting G., Li J., Davis H., Heffelfinger S., Desai P., Roy-Chaudhury P. Development of a local perivascular paclitaxel delivery system for hemodialysis vascular access dysfunction: polymer preparation and in vitro activity. Blood Purif. 2006, 24(3):289-298.
34. Pires N.M., Eefting D., de Vries M.R., Quax P.H., Jukema J.W. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007, 93(8):922-927.
35. El-Kurdi M.S., Hong Y., Stankus J.J., Soletti L., Wagner W.R., Vorp D.A. Transient elastic support for vein grafts using a constricting microfibrillar polymer wrap. Biomaterials 2008, 29(22):3213-3220.
36. Pearce C.G., Najjar S.F., Kapadia M.R., Murar J., Eng J., Lyle B., Aalami O.O., Jiang Q., Hrabie J.A., Saavedra J.E., Keefer L.K., Kibbe M.R. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic. Biol. Med. 2008, 44(1):73-81.
37. Etheredge E.E., Haid S.D., Maeser M.N., Sicard G.A., Anderson C.B. Salvage operations for malfunctioning polytetrafluoroethylene hemodialysis access grafts. Surgery 1983, 94(3):464-470.
38. Palder S.B., Kirkman R.L., Whittemore A.D., Hakim R.M., Lazarus J.M., Tilney N.L. Vascular access for hemodialysis. Patency rates and results of revision. Ann. Surg. 1985, 202(2):235-239.
39. Zhu W., Masaki T., Bae Y.H., Rathi R., Cheung A.K., Kern S.E. Development of a sustained-release system for perivascular delivery of dipyridamole. J. Biomed. Mater. Res. B Appl. Biomater. 2006, 77(1):135-143.
40. C.M. Terry, E.G. Kholmovski, H. Li, S.E. Kim, I. Zhuplatov, K.D. Fowers, R. Rameth, A.K. Cheung, Magnetic resonance imaging to monitor the location of a biodegradable drug delivery polymer gel after perivascular injection, Academic Radiology (submitted for publication).
41. Matthes K., Mino-Kenudson M., Sahani D.V., Holalkere N., Fowers K.D., Rathi R., Brugge W.R. EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest. Endosc. 2007, 65(3):448-453.
42. Kahan B.D., Napoli K.L., Kelly P.A., Podbielski J., Hussein I., Urbauer D.L., Katz S.H., Van Buren C.T. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transpl. 2000, 14(2):97-109.
43. Taylor P.J., Salm P., Lynch S.V., Pillans P.I. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 2000, 22(5):608-612.
44. Streit F., Armstrong V.W., Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin. Chem. 2002, 48(6 Pt 1):955-958.
45. Boernsen K.O., Egge-Jacobsen W., Inverardi B., Strom T., Streit F., Schiebel H.M., Benet L.Z., Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J. Mass Spectrom. 2007, 42(6):793-802.
46. Wang S., Miller A. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin. Chem. Lab. Med. 2008, 46(11):1631-1634.
47. Seger C., Tentschert K., Stoggl W., Griesmacher A., Ramsay S.L. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. Nat. Protoc. 2009, 4(4):526-534.
48. Zhu W. Sustained Perivascular Drug Delivery for the Prevention of Hemodialysis Arteriovenous Graft Stenosis. Dept. of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 2006 2006, pp. xiv, 156 leaves.